Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Albuquerque, Luiz Eduardo T ^a   Tso, Leopoldo O ^b   Saconato, Humberto ^c   Albuquerque, Maria Cecília R M ^d   Macedo, Cristiane R ^e  

^a Human Reproduction Section   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Faculdade Integrado de Campo Mourão   (Brazil)

^d Fertivitro Centro de Reprodução Humana   (Brazil)

^e Brazilian Cochrane Center   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; GOSERELIN; LEUPRORELIN; NAFARELIN; TRIPTORELIN; FERTILITY PROMOTING AGENT; GONADORELIN;

DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; EMBRYO TRANSFER; HUMAN; IN VITRO FERTILIZATION; INTENTION TO TREAT ANALYSIS; MULTIPLE PREGNANCY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PITUITARY DOWN REGULATION; PREGNANCY RATE; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FERTILIZATION IN VITRO; HYPOPHYSIS; LIVE BIRTH; META ANALYSIS; METHODOLOGY; OVARY; OVULATION INDUCTION; PHYSIOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DELAYED-ACTION PREPARATIONS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; LIVE BIRTH; OVARY; OVULATION INDUCTION; PITUITARY GLAND; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84874803297     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002808.pub3     Document Type: Review

References (58)

1. Dada T, Salha O, Baillie HS, Sharma V. A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study. Human Reproduction 1999;14(2):288-93.
2. Dal Prato L, Borini A, Trevisi MR, Bonu MA, Sereni E, Flamigni C. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study. Human Reproduction 2001;16(7):1409-14.
3. Devreker F, Van der Bergh M, Govaerts I, Gervy C, Bertrand E, Englert Y. The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate. Fertility & Sterility 1996;65(1):122-6.
4. Dor J, Bider D, Shulman A, Levron J, Shine S, Mashiach S, et al.Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro - results of a prospective, randomized in-vitro fertilization study. Human Reproduction 2000;15(6):1225-30.
5. Ferrari B, Baruzi L, Lanna M, Coppola F. Ovarian Response and pregnancy outcome related to midfollicular LH levels en down-regulated women undergoing assisted reproduction. Journal of Reproductive Medicine 2004;49:148-52.
6. Gianaroli L, Ferraretti AP, Feliciani E, Tabanelli C, Magli C, Fortini D. Prospective randomized study of D-Trp6-LHRH versus buserelin in long desensitization protocols for medically assisted conception cycles. Human Reproduction 1994;9(2):220-5.
7. Harrison RF, Kondaveeti U, Barry-Kinsella C, Gordon A, Drudy L, Cottell E, et al.Should gonadotropin-releasing hormone down-regulation therapy be routine in in vitro fertilization?. Fertility & Sterility 1994;62(3):568-73.
8. Hsieh YY, Chang CC, Tsai HD. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwanese Journal of Obstetrics & Gynecology 2008;47(1):66-74.
9. Isikoglu M, Ozdem S, Berkkanoglu M, Jamal H, Senturk Z, Ozgur K. Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. Human Reproduction 2007;22(6):1657-61.
10. Librati C, Hocke C, Filet JP, Papaxanthos A, Mene D, Dulucq MC, et al.Can the galenic form of GnRH agonist used during long IVF protocol vary the pregnancy rate? [Le type d'analogue de la GnRH utilisé au cours des protocoles longs en FIV peut-il influencer les taux de grossesse?]. Contraception, Fertilité, Sexualité 1996;24(10):762-6.
11. Porcu E, Fabbri R, Dal Prato L, Longhi M, Seracchioli R, Flamigni C. Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results. Fertility & Sterility 1994;62(1):126-32.
12. Porcu E, Filicori M, Dal Prato L, Fabbri R, Seracchioli R, Colombi C, et al.Comparison between depot leuprorelin and daily buserelin in IVF. Journal of Assisted Reproduction Genetics 1995;12(1):15-9.
13. Safdarian L, Mohammadi FS, Alleyassin A, Aghahosseini M, Meysamie A, Rahimi E. Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916). Human Reproduction 2007;22(9):2449-54.
14. Tapanainen J, Hovatta O, Juntunen K, Martikaineu H, Ratsula K, Tulppala M, et al.Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: a randomized comparative study. Human Reproduction 1993;8(12):2052-5.
15. Tapanainen JS, Hovatta O. Pituitary down-regulation with goserelin (Zoladex) for in vitro fertilisation. British Journal of Obstetrics & Gynaecology 1994;101(10):27-8.
16. Tehraninejad ESh, Nekoo EA, Ezabadi Z, Rashidi BH, Amirchaghmaghi E. Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles. Archives of Medical Sciences 2010;6(6):2909-12.
17. Tsai HD, Chen CM, Lo HY, Chang CC. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Human Reproduction 1995;10(11):2909-12.
18. Devroey P, Mannaerts B, Smitz J, Coelingh Bennink H, Van Steirteghem A. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Human Reproduction 1994;9(6):1064-9.
19. Dicker D, Goldman GA, Ashkenazi J, Feldberg D, Shelef M, Goldman JA. Combination of long and short term GnRH analogue protocols: a new therapeutic approach to persistent high progesterone levels in IVF cycles. Human Reproduction 1991;6(2):203-5.
20. Fábregues F, Balasch J, Creus M, Cívico S, Carmona F, Puerto B, et al.Long-term down-regulation does not improve pregnancy rates in an in vitro fertilization program. Fertility & Sterility 1998;70(1):46-51.
21. Geber S, Sales L, Sampaio MA. Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. Journal of Assisted Reproduction and Genetics 2002;19(7):313-8. [MEDLINE: 12168731]
22. Gonen Y, Dirnfeld M, Goldman S, Koifman M, Abramovici H. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; Decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). Journal of In Vitro Fertilization & Embryo Transfer 1991;8(5):254-9.
23. Hazout A, Ziegler D, Cornel C, Fernandez H, Lelaidier C, Frydman R. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation. Fertility & Sterility 1993;59(3):596-600.
24. Isler V, Lunenfeld E, Potashnik G, Levy J. Ovarian stimulation concomitant with pituitary-ovarian axis suppression by different GnRH agonist. International Journal of Fertility 1991;36(2):121-7.
25. Lipitz S, Ben-Rafael Z, Dor J, Shalev J, Elenbogen A, Levran D, et al.Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols. Gynecologic & Obstetric Investigation 1989;28:31-4.
26. Lopes A, Barriere P, Charbonnel B, Paillard B. Value of short-term use of a gonadorelin analog in an in vitro fertilization program [Intérêt de l'utilisation brève d'un analogue de la gonadoreline dans un programme de fécondation in vitro]. Presse Medicale 1986;15(41):2074.
27. Lorusso F, Depalo R, Selvaggi L. Relationship between gonadotropin releasing hormone agonist dosage and in vitro fertilization outcome. Gynecological Endocrinolology 2004;18:69-73.
28. Meldrum DR. Patient preparation and standard stimulation regimens using gonadotropin-releasing hormone agonists. Clinical Obstetrics and Gynecology 2006;49(1):4-11.
29. Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: a comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact. Human Reproduction 1995;10(5):1042-4. [MEDLINE: 7657737;: 95386617]
30. Parinaud J, Oustry P, Perineau M, Rène JM, Monroziès X, Pontonnier G. Randomized trial of three luteinizing hormone-releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program. Fertility & Sterility 1992;57(6):1265-8.
31. Ron-El R, Herman A, Golan A, Soffer Y, Nachum H, Caspi E. Ultrashort gonadotropin-releasing hormone agonist (GnRH-a) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone. Fertility & Sterility 1992;58(6):1164-8.
32. Schmutzler RK, Reichert C, Diedrich K, Wildt L, Diedrich CH, Al-Hasani S, et al.Comparison of a long acting and a short acting GnRH analogue/gonadotropin stimulation for in-vitro fertilization under various indications [Vergleich eines langwirksamen und kurzwirksamen GnRH-Analogs in Kombination mit Gonadotropinen zur In-vitro-Fertilisierung unter verschiedenen Indikationsstellungen [German]]. Geburtsh u Frauenheilk 1988;49:85-90.
33. Schmutzler RK, Reichert C, Diedrich K, Wildt L, Diedrich Ch, Al-Hasani S, et al.Combined GnRH-agonis/gonadotrophin stimulation for in-vitro fertilization. Human Reproduction 1988;3(2):29-33.
34. Sonntag B, Kiesel L, Nieschlag E, Behre HM. Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART. Journal of Assisted Reproduction and Genetics 2005;22(7):277-83.
35. Yang YS, Ho HN, Lien YR, Hwang JL, Melinda S, Lin HR, et al.The use of a long-acting gonadotropin-releasing hormone analog (D-Trp-6-LHRH) for improvement of ovarian stimulation in assisted conception programs. Journal of the Formosan Medical Association 1991;90:1081-5.
36. Balasch J, Gomez F, Casamitjana R, Carmona F, Rivera F, Vanrell JA. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Human Reproduction 1992;7(9):1230-4.
37. Bussenot I, Azoulay-Barjonet C, Parianaud J. Modulation of the steroidogenesis of cultured human granulosa-lutein cells by gonadotropin-releasing hormone analogs. Journal of Clinical Endocrinology & Metabolism 1993;76(5):1376-9.
38. Fleming R, Coutts JRT. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertility & Sterility 1986;45:226.
39. Gaetje R. Influence of gonadotrophin releasing hormone (GnRH) and a GNRH-agonist on granulosa cell steroidogenesis. Clinical & Experimental Obstetrics & Gynecology 1994;21(3):164-9.
40. Gerrero HE, Stein P, Asch RH, de Fried EP, Tesone M. Effect of a gonadotropin-releasing hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells. Fertility & Sterility 1993;59(4):803-8.
41. GRADE Working Group. GRADE Profiler Software. GRADE Working Group, 2011.
42. Herman A, Ron-El R, Golan A, Nachum H, Soffer Y, Caspi E. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Human Reproduction 1992;7:465-8.
43. Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD006919.pub3]
44. Meldum DR, Wisot A, Hamilton F, Gutlay AL, Kempton W, Huynh D. Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. Fertility & Sterility 1989;51:455-9.
45. Minaretzis D, Jakubowski M, Mortola J, Pavlou SN. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. Journal of Clinical Endocrinology & Metabolism 1995;80(2):430-4.
46. Néstor JJ Jr. Development of agonistic LHRH analogs. In: Vickery BH, Néstor JJ, Jr, Hafez ESE editor(s). LHRH and its analogs - contraceptive and therapeutic applications. Lancaster, UK: MTP Press, 1984:3.
47. Parinaud J, Beaur A, Bourreau E, Vieitez G, Pontonnier G. Effect of a luteinizing hormone-releasing hormone agonist (buserelin) on steroidogenesis of cultured human preovulatory granulosa cells. Fertility & Sterility 1988;50(4):597-602.
48. Peng C, Fan NC, Ligier M, Vaananen J, Leung PC. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GNRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 1994;135(5):1740-6.
49. Porter RN, Smith W, Craft IL. Induction of ovulation for in vitro fertilisation using buserelin and gonadotrophins. Lancet 1984;2:1284.
50. Rabin D, McNeil LW. Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. Journal of Clinical Endocrinology & Metabolism 1980;51:873.
51. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
52. Sanders LM, Kent JS, McRae GI, Vickery BH, Tice TR, Lawis DH. Controlled release of a LH-RH analogue from poly (d, l, lactidecoglycolide) microspheres. Journal of Pharmaceutical Sciences 1984;73(9):1294-7.
53. Testart J, Lefevre B, Gougeon A. Effects of gonadotrophin releasing hormone agonists (GnRHa) on follicle and oocyte quality. Human Reproduction 1993;8:511-8.
54. Uemura T, Namiki T, Kimura A, Yanagisawa T, Minaguchi H. Direct effects of gonadotropin-releasing hormone on the ovary in rats and humans. Hormone Research 1994;41(Suppl 1):7-13.
55. Van Uem JF, Garcia JE, Liu HC, Rosenwaks Z. Clinical aspects with regard to the occurrence of an endogenous LH surge in gonadotropin induced normal menstrual cycles. Journal of In Vitro Fertilization & Embryo Transfer 1986;3:345.
56. Vauthier D, Lefebvre G. The use of gonadotropin-releasing hormone analogs for in vitro fertilization: comparison between the standard form and long-acting formulation of D-Trp-6-luteinizing hormone-releasing hormone. Fertility & Sterility 1989;51:100-4.
57. Vickery BH, Néstor JJ. Luteinizing hormone-releasing hormone analogs: development and mechanism of action. Seminars in Reproductive Endocrinology 1987;5:353.
58. Wong JM, Forrest KA, Snabes MC, Zhao SZ, Gersh GE, Kennedy SH. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Human Reproduction Update 2001;7(1):92-101.